Skip to main content
Caplight Logo









CoImmune, Inc.

CoImmune, Inc.

Private
Durham, North CarolinaHealthcare & Life Scienceshttp://benecyte.com

Last Round

Series A

Nov 10, 2020

Total Funding Raised

$56.1M

Company Overview

CoImmune, Inc. is a biotechnology company that specializes in the development of immuno-oncology therapies based on its two proprietary platform technologies, an autologous RNA-loaded dendritic cell technology and an allogeneic CAR-CIK technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cellular immunotherapyimmuno-oncologycell therapy for canceroff-the-shelf cell therapyallogeneic cell therapyCAR-CIK therapyautologous dendritic cell therapydendritic cell therapycytokine-induced killer cellsCIK cellsCAR-T alternativerenal cell carcinomaacute lymphoblastic leukemiacord blood cell therapyclinical-stage biotechSEAKER platformOrexiCAR technology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CoImmune, Inc. Comparables

Compare CoImmune, Inc. with similar companies based on industry and business-model similarity.

CoImmune, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Diakonos Oncology
82%
CellxLife
80%
AiVita Biomedical
74%

CoImmune, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 10, 2020
Corporate FundingFeb 13, 2019

CoImmune, Inc. Investors

Notable investors and investment history

CoImmune, Inc. investors
InvestorRounds
DSC InvestmentSeries A
Korea Investment PartnersSeries A
SCM LifescienceCorporate Funding, Series A
Brain Asset Management Co.,Ltd.Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2020

    $45M round with SCM Lifescience and Genexine Inc.

  • Feb 13, 2019

    $11.1M raised from SCM Lifescience and Genexine Inc.

CoImmune, Inc. Filings

Explore SEC and related filing metadata, where available.

CoImmune, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CoImmune, Inc.'s valuation, stock price, and market status.

Is CoImmune, Inc. a public or private company?

CoImmune, Inc. is a private company.

What is the current stock price of CoImmune, Inc.?

CoImmune, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is CoImmune, Inc. worth (valuation)?

Valuation information for CoImmune, Inc. is not publicly available.

Can I buy CoImmune, Inc. stock?

CoImmune, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was CoImmune, Inc.'s last funding round?

CoImmune, Inc.'s most recent funding round was Series A on November 10, 2020.

Who are the main investors in CoImmune, Inc.?

Key investors in CoImmune, Inc. include Korea Investment Partners, Brain Asset Management Co.,Ltd..

Will CoImmune, Inc. IPO soon?

No public IPO plans have been announced for CoImmune, Inc..

How can I track CoImmune, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CoImmune, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDurham, North Carolina
Year Founded2019
Last FundingNov 10, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?